Literature DB >> 29427787

ZNF462 and KLF12 are disrupted by a de novo translocation in a patient with syndromic intellectual disability and autism spectrum disorder.

Nele Cosemans1, Laura Vandenhove1, Jarymke Maljaars2, Hilde Van Esch3, Koenraad Devriendt3, Amanda Baldwin4, Jean-Pierre Fryns3, Ilse Noens2, Hilde Peeters5.   

Abstract

We describe a patient with a de novo balanced translocation 46,XY,t(9; 13)(q31.2; q22.1) and autism spectrum disorder, intellectual disability, a metopic craniosynostosis, a corpus callosum dysgenesis and dysmorphic facial features, most notably ptosis. Breakpoint mapping was performed by means of targeted locus amplification (TLA) and sequencing, because conventional breakpoint mapping by means of fluorescent in situ hybridization and long-range PCR was hampered by a complex submicroscopic rearrangement. The translocation breakpoints directly affected the genes KLF12 (chromosome 13) and ZNF462 (chromosome 9). The latter gene was disrupted by multiple breakpoints, resulting in the loss of three fragments and a rearrangement of the remaining fragments. Therefore, haploinsufficiency of ZNF462 was assumed. Loss-of-function variants in ZNF462 have recently been published by Weiss et al. (2017) in a series of eight patients from six independent families delineating the ZNF462-associated phenotype. The latter closely matches with the clinical features of the current translocation patient. Besides, no direct evidence for an association of KLF12 to the phenotypic features was found. Therefore, we conclude that the phenotype of the current patient is mainly caused by the disruption of ZNF462. We present clinical data from birth to adulthood and data on the cognitive and behavioral profile of the current patient which may add to a more precise counseling and surveillance of development in young children with ZNF462 mutations. In addition, the current case illustrates that TLA is an efficient method for determining complex chromosomal breakpoints.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Corpus callosum; Craniosynostosis; Ptosis; Syndromic intellectual disability/autism spectrum disorder; Targeted locus amplification

Mesh:

Substances:

Year:  2018        PMID: 29427787     DOI: 10.1016/j.ejmg.2018.02.002

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  4 in total

1.  Phenotype delineation of ZNF462 related syndrome.

Authors:  Paul Kruszka; Tommy Hu; Sungkook Hong; Rebecca Signer; Benjamin Cogné; Betrand Isidor; Sarah E Mazzola; Jacques C Giltay; Koen L I van Gassen; Eleina M England; Lynn Pais; Charlotte W Ockeloen; Pedro A Sanchez-Lara; Esther Kinning; Darius J Adams; Kayla Treat; Wilfredo Torres-Martinez; Maria F Bedeschi; Maria Iascone; Stephanie Blaney; Oliver Bell; Tiong Y Tan; Marie-Ange Delrue; Julie Jurgens; Brenda J Barry; Elizabeth C Engle; Sarah K Savage; Nicole Fleischer; Julian A Martinez-Agosto; Kym Boycott; Elaine H Zackai; Maximilian Muenke
Journal:  Am J Med Genet A       Date:  2019-07-30       Impact factor: 2.802

2.  Empty Sella Syndrome Associated with Growth Hormone Deficiency: the First Case Report of Weiss-Kruszka Syndrome.

Authors:  Jisun Park; Dong Jun Ha; Go Hun Seo; Seri Maeng; Sung Mo Kang; Sujin Kim; Ji Eun Lee
Journal:  J Korean Med Sci       Date:  2021-05-10       Impact factor: 2.153

3.  A Nonsense Variant of ZNF462 Gene Associated With Weiss-Kruszka Syndrome-Like Manifestations: A Case Study and Literature Review.

Authors:  Shaozhi Zhao; Chen Miao; Xiaolei Wang; Yitong Lu; Hongwei Liu; Xinwen Zhang
Journal:  Front Genet       Date:  2022-02-07       Impact factor: 4.599

4.  The genetic cause of intellectual deficiency and/or congenital malformations in two parental reciprocal translocation carriers and implications for assisted reproduction.

Authors:  Dehua Cheng; Shimin Yuan; Liang Hu; Duo Yi; Keli Luo; Fei Gong; Changfu Lu; Guangxiu Lu; Ge Lin; Yue-Qiu Tan
Journal:  J Assist Reprod Genet       Date:  2020-10-22       Impact factor: 3.412

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.